Medico Intercontinental (BSE: MIL) is loss-making over the last 12 months, losing ₹3.97 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹25.48, 41% below its 52-week high. Sales grew 3.3% a year over 3 years. Debt is 2.08× equity. It is a small-cap company with a market cap of ₹25 Cr, ranked 139th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 28% over the past year.
- ₹25.90
- ₹25.90
- ₹24.75
- ₹25.16
- 3.7K
Health check
- ReturnsBehind
−28.1% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +3.3% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -1.7% vs peer median 17.9%.
- Balance sheetStretched
Debt 2.08× equity, operating profit doesn’t cover interest, Piotroski 4 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹25 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 0.54
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −6.6%
- Peers 14.7%
- ROCE
- −1.7%
- Peers 17.9%
- Debt to equity
- 2.08
- Debt ₹67 Cr
- EPS (TTM)
- −₹3.97
- OPM (TTM)
- 1.9%
- Net margin −4.7%
- Sales growth
- −3.0%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.30
- EV/EBITDA 24.9
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −6.6%.
- Debt is 2.08× equity.
- Quarterly sales down 3.0% on a year ago.
- 41% below its 52-week high.
About Medico Intercontinental
Medico Intercontinental Limited engages in the trading of pharmaceutical products. It offers products in the gastro, uro, nutrition, cosmetology, and other areas, as well as provides health devices and hospital related products. The company also provides general and derma range products in various forms, such as tablets, soft gelatine, capsules, dental, ointments, powders and sprays, liquids, ayurvedics, injectables, dry syrup, suspension, drops,…
- Headquarters
- Ahmedabad
- Employees
- 41
- Sector
- Healthcare
- ISIN
- INE858Q01019
- Website
- medicointercontinental.com
Price range
- Avg volume (3M)
- 1.9K
- 1-year return
- minus 28.1%
- From 52-week high
- minus 40.7%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| MILMedico Intercontinental | 25.48 | plus 1.27% | 25 | – | 0.54 | −1.7% | −6.6% | 1.9% | 3.3% | – | 0.00% | minus 28.1% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 21.4 | 20.4 | 19.8 | 22.5 | 20.7 | |
| 20.7 | 21.3 | 18.3 | 20.9 | 21.4 | |
| 0.7 | −0.9 | 1.6 | 1.6 | −0.7 | |
| 3.1% | −4.4% | 8.0% | 7.2% | −3.3% | |
| 0.3 | 0.6 | 0.3 | 0.1 | 0.1 | |
| 2.4 | 2.1 | 1.9 | 1.8 | 1.9 | |
| 0.6 | 2 | 1.4 | 1.4 | 1.2 | |
| −2 | −4.3 | −1.4 | −1.6 | −3.7 | |
| −23.3% | −4.5% | −20.3% | −51.4% | −10.5% | |
| −0.7 | −1.7 | −1.7 | −0.7 | −1.4 | |
| -0.68 | -1.65 | -0.22 | -0.65 | -1.45 |
Profit & loss
- Sales CAGR 3Y
- +3.3%
- ROE
- −6.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 76.2 | 71.4 | 95.3 | 84.1 | |
| – | minus 6.4% | +33.6% | minus 11.8% | |
| 70.9 | 65.5 | 87.1 | 81.1 | |
| 5.3 | 5.9 | 8.2 | 3 | |
| 7.0% | 8.3% | 8.6% | 3.5% | |
| 0.5 | 0.4 | 0.4 | 0.7 | |
| 0.6 | 0.5 | 1 | 8 | |
| 0.2 | 0.3 | 0.8 | 5.4 | |
| −0.1 | −0.1 | −0 | 0.4 | |
| 4.9 | 5.4 | 6.8 | −9.3 | |
| 27.0% | 27.4% | 27.4% | −18.7% | |
| 3.6 | 3.9 | 5.1 | −3.2 | |
| – | +9.4% | +28.1% | minus 163.3% | |
| 5.61 | 3.95 | 5.06 | -3.20 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 10 | 10 | 10 | 10 | |
| 31.2 | 35 | 40.1 | 36.9 | |
| 4.7 | 4.9 | 16.9 | 67.2 | |
| 13 | 6.2 | 9.9 | 3.1 | |
| 58.9 | 56 | 76.9 | 117 | |
| 8 | 16.4 | 14 | 38 | |
| 6.6 | 14 | 10.5 | 1.2 | |
| 0 | 0 | 3 | 2.5 | |
| 6.8 | 3.4 | 2.2 | 6 | |
| 37.5 | 22.3 | 47.2 | 69.6 | |
| 58.9 | 56 | 76.9 | 117 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −10.1 | 5.6 | −6.3 | 17.1 | |
| −5.4 | −8.5 | −4.9 | 2.2 | |
| 20.4 | −0.5 | 10.1 | −15.6 | |
| 4.9 | −3.4 | −1.1 | 3.7 | |
| −0.4 | −1.2 | −1.9 | −4.6 | |
| −10.5 | 4.3 | −8.2 | 12.4 | |
| – | −0.1 | – | – |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.